The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

NCT07180459 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Hepatocellular Carcinoma

Interventions

PROCEDURE: E-TACE
DRUG: Donafenib

Sponsor

Xuhua Duan